newsfilter
← Latest News
GlobeNewswire·

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects to Report One-Year